Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.3 USD | -1.23% | +1.14% | -11.93% |
Financials (USD)
Sales 2024 * | 4.09B | Sales 2025 * | 4.39B | Capitalization | 6.75B |
---|---|---|---|---|---|
Net income 2024 * | 475M | Net income 2025 * | 648M | EV / Sales 2024 * | 2.45 x |
Net Debt 2024 * | 3.27B | Net Debt 2025 * | 1.79B | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
11.1
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.18% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | -1.23% | ||
1 week | +1.14% | ||
Current month | -10.05% | ||
1 month | -11.07% | ||
3 months | -12.04% | ||
6 months | -17.34% | ||
Current year | -11.93% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 215 M€ | +11.68% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 108.3 | -1.23% | 401,342 |
24-04-23 | 109.7 | +0.77% | 376,841 |
24-04-22 | 108.8 | -1.01% | 514,011 |
24-04-19 | 109.9 | +0.61% | 756,914 |
24-04-18 | 109.3 | +2.03% | 564,463 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.93% | 6.75B | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- JAZZ Stock